Analyst Ratings for IGM Biosciences IGM Biosciences (NASDAQ:IGMS) has observed the following analyst ratings within the last quarter: Benzinga · May 17, 2022
Why Did Truist Lower IGM Biosciences' Price Target? Truist has lowered the price target on IGM Biosciences Inc (NASDAQ:IGMS) to $74 from $80. The analyst Asthika Goonewardene says that the lower price target reflects the Company's Q4 results, deal financials, and increased cost to IGM Biosciences in its Sanofi SA (NASDAQ:SNY) collaboration deal. Related: IGM Biosciences Shares Surge After Oncology / Immunology Pact With Sanofi.… Benzinga · Mar 30, 2022
10 Biggest Price Target Changes For Wednesday Morgan Stanley raised the price target on IGM Biosciences, Inc. (NASDAQ: IGMS) from $25 to $30. IGM Biosciences shares fell 4% to $28.32 in pre-market trading. Benzinga · Mar 30, 2022
Mid-Day Market Update: Crude Oil Down 2.5%; IGM Biosciences Shares Jump U.S. stocks traded higher midway through trading, with the Dow jumping over 250 points on Tuesday. Benzinga · Mar 29, 2022
Mid-Morning Market Update: Markets Open Higher; McCormick Profit Beats Estimates U.S. stocks opened on a strong note on Tuesday, with the Dow jumping around 350 points this morning. Benzinga · Mar 29, 2022
Recap: IGM Biosciences Q4 Earnings IGM Biosciences (NASDAQ:IGMS) reported its Q4 earnings results on Tuesday, March 29, 2022 at 06:00 AM. Here's what investors need to know about the announcement. Benzinga · Mar 29, 2022